Head-To-Head Comparison: Symmetry Medical (SMA) vs. MiMedx Group (MDXG)
Symmetry Medical (NYSE: SMA) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.
Insider & Institutional Ownership
69.4% of MiMedx Group shares are owned by institutional investors. 12.4% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Symmetry Medical and MiMedx Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Symmetry Medical and MiMedx Group, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MiMedx Group has a consensus target price of $17.00, suggesting a potential upside of 49.25%.
Valuation & Earnings
This table compares Symmetry Medical and MiMedx Group’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MiMedx Group||$245.01 million||5.16||$11.97 million||$0.31||36.74|
MiMedx Group has higher revenue and earnings than Symmetry Medical. Symmetry Medical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
MiMedx Group beats Symmetry Medical on 8 of the 8 factors compared between the two stocks.
About Symmetry Medical
Symmetry Medical Inc. (Symmetry) is a medical device solutions company, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Company designs, develops and offers worldwide production and supply chain capabilities for these products to customers in the orthopedic industry, and other medical device markets (including but not limited to arthroscopy, dental, laparoscopy, osteobiologic, and endoscopy segments). It also manufactures specialized non-healthcare products, primarily in the aerospace industry. The Company operates in two segments: original equipment manufacturer (OEM) solutions and symmetry surgical. On August 15, 2011, the Company acquired PSC Industries, Inc’s Olsen Medical division. On December 29, 2011 it acquired the surgical instruments product portfolio from Codman & Shurtleff, Inc., a Johnson & Johnson Company.
About MiMedx Group
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
Receive News & Ratings for Symmetry Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symmetry Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.